Long Noncoding RNAs Act as Novel Biomarkers for Hepatocellular Carcinoma: Progress and Prospects.
Han BaoHongying SuPublished in: BioMed research international (2017)
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and confers a poor prognosis. Novel diagnostic or prognostic biomarkers and effective therapeutic targets for HCCs are urgently needed. Currently, dozens of long noncoding RNAs (lncRNAs) have been identified as playing critical roles in cancer development and progression. Advanced studies have shown that several well-known lncRNAs are dysregulated in HCC tissue as compared to adjacent noncancerous tissue. Furthermore, highly stable cell-free circulating nucleic acids (cfCNAs), including lncRNAs, aberrantly expressed in the plasma of HCC patients, have been detected. In this review, we focus on the most extensively investigated lncRNAs in HCC and discuss the potential of HCC-related lncRNAs as novel biomarkers for early diagnosis and prognosis.
Keyphrases
- poor prognosis
- cell free
- network analysis
- genome wide analysis
- genome wide identification
- long non coding rna
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- multidrug resistant
- papillary thyroid
- transcription factor
- mass spectrometry
- squamous cell carcinoma
- high resolution
- risk assessment
- childhood cancer
- young adults
- human health
- circulating tumor
- lymph node metastasis
- circulating tumor cells